Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Buy

Wall Street Data Solutions Rating

Buy

A

Revolution Medicines, Inc. Common Stock (RVMD)

Biological Products, (no Disgnostic Substances)

https://www.revmed.com

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

700 SAGINAW DR
REDWOOD CITY, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/13/2020

Market Cap

7,179,336,220

Shares Outstanding

163,800,000

Weighted SO

163,796,510

Total Employees

N/A

Upcoming Earnings

08/07/2024

Similar Tickers

BPMC --.--%

SANA --.--%

KYMR --.--%

GLUE --.--%

TCRR --.--%

BDTX --.--%

BCEL --.--%

PASG --.--%

AKRO --.--%

Beta

1.4390

Last Div

0.0000

Range

15.44-48.61

Chg

-0.5400

Avg Vol

1521412

Mkt Cap

7179336220

Exch

NASDAQ

Country

US

Phone

650 481 6801

DCF Diff

38.1755

DCF

4.8746

Div Yield

0.0000

P/S

9675.6553

EV Multiple

-11.7481

P/FV

4.3845

Div Yield %

0.0000

P/E

-13.6705

PEG

0.5398

Payout

0.0000

Current Ratio

15.4248

Quick Ratio

15.4248

Cash Ratio

2.6176

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

1013.1057

CCC

-1013.1057

Gross Margin

-13.2358

Op Margin

-809.6132

Pretax Margin

-704.4892

Net Margin

-699.7399

Eff Tax Rate

-0.0028

ROA

-0.2871

ROE

-0.3457

ROCE

-0.3527

NI/EBT

0.9933

EBT/EBIT

0.8702

EBIT/Rev

-809.6132

Debt Ratio

0.0483

D/E

0.0540

LT Debt/Cap

0.0466

Total Debt/Cap

0.0512

Int Coverage

-64.6714

CF/Debt

-5.8321

Equity Multi

1.1171

Rec Turnover

0.0000

Pay Turnover

0.3603

Inv Turnover

0.0000

FA Turnover

0.0074

Asset Turnover

0.0004

OCF/Share

-3.0870

FCF/Share

-3.1500

Cash/Share

9.6324

OCF/Sales

-687.0445

FCF/OCF

1.0204

CF Coverage

-5.8321

ST Coverage

-61.1842

CapEx Coverage

-48.9333

Div&CapEx Cov

-48.9333

P/BV

4.3845

P/B

4.3845

P/S

9675.6553

P/E

-13.6705

P/FCF

-13.8010

P/OCF

-13.9231

P/CF

-13.9231

PEG

0.5398

P/S

9675.6553

EV Multiple

-11.7481

P/FV

4.3845

DPS

0.0000

Latest Headlines (EST)

Benzinga Nov 16, 15:27 Cancer Player Revolution Medicines Gets Bullish Rating: Here's Details GlobeNewswire Inc. Nov 09, 09:10 Revolution Medicines Completes Acquisition of EQRx GlobeNewswire Inc. Nov 08, 11:30 Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition Benzinga Nov 07, 15:00 What 6 Analyst Ratings Have To Say About Revolution Medicines GlobeNewswire Inc. Oct 13, 11:50 Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting

Revenue Product Segmentation